Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections

被引:20
作者
Low, DE
Felmingham, D
Brown, SD
Rangaraju, M
Nusrat, R
机构
[1] Univ Toronto, Dept Microbiol, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[2] GR Micro Ltd, London NW1 3ER, England
[3] CMI, Wilsonville, OR 97070 USA
[4] Aventis, F-93235 Romainville, France
[5] Aventis, Bridgewater, NJ 08807 USA
关键词
telithromycin; community-acquired pneumonia; acute exacerbations of bronchitis; acute maxillary sinusitis;
D O I
10.1016/j.jinf.2004.03.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives. To investigate the correlation between in vitro susceptibility of isolates and clinical outcomes with telithromycin in respiratory tract infections. Methods. The activity of telithromycin was determined by in vitro susceptibility testing of key respiratory tract pathogens isolated from patients with community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute maxillary sinusitis enrolled in 14 Phase III/IV clinical trials evaluating the clinical efficacy of telithromycin. Results. In this pooled analysis, telithromycin mode minimum inhibitory concentration (MIC) and MIC90, respectively, were: 0.016 and 0.03 mg/l against Streptococcus pneumoniae (n = 626); 0.03 and 0.5 mg/l for penicillin-resistant S. pneumoniae (n = 56); 0.03 and 1 mg/l for erythromycin-resistant S. pneumoniae (n = 81); 2 and 4 mg/l against Haemophilus influenzae (including beta-lactamase producers; n = 627); both 0.12 mg/l for Moraxella catarrhalis (n = 159); and both 0.25 mg/l for Staphylococcus aureus (n = 124). Telithromycin (5 or 7-10 days) resulted in overall clinical and bacteriologic success rates of 88.1% (1593/1808) and 89% (1593/1789), respectively. Conclusions. High levels of in vitro susceptibility to telithromycin are paralleled by high rates of clinical cure and bacteriologic eradication. (C) 2004 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:115 / 125
页数:11
相关论文
共 51 条
  • [1] Outpatient visits for infectious diseases in the united states, 1980 through 1996
    Armstrong, GL
    Pinner, RW
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (21) : 2531 - 2536
  • [2] Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis
    Aubier, M
    Aldons, PM
    Leak, A
    McKeith, DD
    Leroy, B
    Rangaraju, M
    Bienfait-Beuzon, C
    [J]. RESPIRATORY MEDICINE, 2002, 96 (11) : 862 - 871
  • [3] Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
    Aubier, M
    Verster, R
    Regamey, C
    Geslin, P
    Vercken, JB
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (06) : 1312 - 1320
  • [4] Acute exacerbations of chronic bronchitis - An international comparison
    Ball, P
    Make, B
    [J]. CHEST, 1998, 113 (03) : 199S - 204S
  • [5] In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae
    Barry, AL
    Fuchs, PC
    Brown, SD
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 2138 - 2140
  • [6] Issues in the management of bacterial sinusitis
    Bishai, WR
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2002, 127 (06) : S3 - S9
  • [7] In vivo efficacy of the new ketolide telithromycin (HMR 3647) in Murine Infection Models
    Bonnefoy, A
    Guitton, M
    Delachaume, C
    Le Priol, P
    Girard, AM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1688 - 1692
  • [8] Brook I, 2000, ANN OTO RHINOL LARYN, V109, P2
  • [9] A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis
    Buchanan, PP
    Stephens, TA
    Leroy, B
    [J]. AMERICAN JOURNAL OF RHINOLOGY, 2003, 17 (06): : 369 - 377
  • [10] Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia
    Carbon, C
    Moola, S
    Velancsics, I
    Leroy, B
    Rangaraju, M
    Decosta, P
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) : 691 - 703